

SOHO France

Hematology Congress

September 24-26, 2025

La Grande Crypte
69 bis Rue Boissière
75 016 PARIS



SCIENTIFIC COMMITTEE

President of the Scientific Committee

Mauricette MICHALLET (Hematology, Centre Léon Bérard, Lyon)

Members of the Scientific Committee

- Amine BELHABRI (Hematology, Centre Léon Bérard, Lyon)
- Sylvain CHOQUET (Hematology, Hôpital Pitié-Salpêtrière, Paris)
- Roch HOUOT (Hematology, CHU de Rennes, Rennes)
- Jean-Jacques KILADJIAN (Hematology, Hôpital Saint-Louis, Paris)
- Xavier LELEU (Hematology, CHU de Poitiers, Poitiers)
- François-Xavier MAHON (Hematology, Institut Bergonié, Bordeaux)
- Anne-Sophie MICHALLET (Hematology, Centre Léon Bérard, Lyon)
- Sophie PARK (Hematology, CHU Grenoble Alpes, Grenoble)
- Christian RECHER (Hematology, Institut Universitaire du Cancer de Toulouse)
- Philippe ROUSSELOT (Hematology, Centre Hospitalier de Versailles, Le Chesnay)

WITH THE INSTITUTIONAL SUPPORT OF OUR PLATINUM PARTNERS



IDEOGEN



NOVARTIS

WITH THE INSTITUTIONAL SUPPORT OF OUR PARTNERS

abbvie



astellas



BeOne



Bristol Myers Squibb^{MC}



Daiichi-Sankyo

Johnson
& Johnson

Lilly

A MEDICINE COMPANY

lipomed
SERVICES TO HEALTH



MENARINI

group

Stemline

A Menarini Group Company

Pfizer



Pierre Fabre

SERVIER



mission bio

sanofi



Le site de l'hématologie

hemato.net

WEDNESDAY 24th SEPTEMBER 2025

08:30 - 09:00 a.m.....Opening

09:00 - 09:30 a.m.....Introduction

Mauricette MICHALLET (President of the Scientific Committee), (Hematology, Lyon)

Jean SIBILIA (Rheumatology, Strasbourg)

09:30 - 10:50 a.m.....Session 1: MYELODYSPLASTIC SYNDROMES

Chair: Sophie PARK (Hematology, Grenoble)

The practical application of IPSS-M in our everyday practice

20 min.

Lin-Pierre ZHAO (Hematology, Paris)

Treatment guidelines for low-risk MDS

20 min.

Mathieu MEUNIER (Hematology, Grenoble)

Pre-emptive or non-emptive treatment of high-risk post-allograft MDS

20 min.

Thomas CLUZEAU (Hematology, Nice)

Discussion

20 min.

10:50 - 11:05 a.m.....COFFEE BREAK & MEET OUR PARTNERS 

11:05 a.m - 12:05 p.m.....THERAPEUTIC CHALLENGES IN PERIPHERAL T-CELL LYMPHOMA

Chair: Vahid ASNAFI (Biological hematology, Paris)



Challenges in the multidisciplinary management of relapsed or refractory peripheral T-cell lymphoma, and expected developments in therapeutic approaches

Julie BRUNEAU (Anatomopathology, Paris), Aurore TOUZART (Biological hematology, Paris)

François LEMONNIER (Hematology, Créteil)

12:05 - 01:05 p.m.....LUNCH BREAK

01:05 - 02:45 p.mSession 2: ACUTE MYELOID LEUKEMIA

Chairs: Arnaud PIGNEUX (Hematology, Bordeaux) & Christian RECHER (Hematology, Toulouse)

Targeting BMP and TAZ/TEAD mechanotransduction pathways alters resistance to AML therapies

20 min.

Sylvain LEFORT (Hematology, Lyon)

State of Art in the Management of AML in 2025

20 min.

Hagop KANTARJIAN (Oncology Hematology, Houston - USA)

Role of IA in Diagnostics

20 min.

Torsten HAERLACH (Oncology Hematology, Munich - Germany)

Significance of plasma metal concentrations in patients with AML

20 min.

Charles DUMONTET (Hematology, Lyon)

Discussion

20 min.

02:45 - 03:00 p.m.....COFFEE BREAK & MEET OUR PARTNERS 

03:00 - 04:20 p.mSession 3: CELL THERAPY AND TRANSPLANTATION

Chair: Anne HUYNH (SFGM-TC president) (Hematology and transplantation, Toulouse)

Managing chronic GVHD in 2025

20 min.

Léonardo MAGRO (Hematology, Lille)

Impact of donor type on transplantation outcome

20 min.

Raynier DEVILLIER (Hematology, Marseille)

Current challenges in the conditioning regimens

20 min.

Maud D'AVENI-PINEY (Hematology, Nancy)

Discussion

20 min.

04:20 - 04:30 p.m.....WHAT'S NEW IN THE INDUSTRIAL KITCHEN?



Single-Cell Multi-Omics Insights into Resistance Mechanisms and Therapy-Persistent Clones

Stéphane COLINET (Sales Executive, Nantes)

THURSDAY 25th SEPTEMBER 2025

08:30 - 09:00 a.mOpening

09:00 - 10:40 a.m.....Session 4: ACUTE LYMPHOBLASTIC LEUKEMIA

Chair: Philippe ROUSSELOT (Hematology, Le Chesnay)

What's new in pediatric ALL-B?

20 min.

Marion STRULLU (Pediatric Immuno-Hematology, Paris)

Results of the GRAALL 2014 protocol

20 min.

Françoise HUGUET (Hematology, Toulouse)

Management of relapsed adult Ph+ ALL

20 min.

Adrien DE VOEGHT (Hematology, Liège - Belgique)

Ferroptosis in ALL-T

20 min.

Guillaume ANDRIEU (Researcher, Paris)

Discussion

20 min.

10:40 - 10:50 a.m.....COFFEE BREAK & MEET OUR PARTNERS 

10:50 a.m - 12:10 p.m....Session 5: LYMPHOMAS

Chair: Sylvain CHOQUET (Hematology, Paris)

NHL T/NK

20 min.

Amira MAROUF (Hematology, Paris)

NHL in patients living with HIV

20 min.

Lionel GALICIER (Internal medicine, Marseille)

Testicular NHL

20 min.

Agathe VELY (Oncology Hematology, Paris)

Discussion

20 min.

12:10 - 12:30 p.m.....ORAL ABSTRACT

12:30 - 01:30 p.m.....LUNCH BREAK & POSTER WALK

01:30 - 02:30 p.m.....MULTIPLE MYELOMA IN FIRST RELAPSE: FOCUS ON NEW THERAPEUTIC OPTIONS

Chair: Alexis TALBOT (Immunology Hematology, Paris)

Introduction

Alexis TALBOT (Immunology Hematology, Paris)

From standard to targeted: Decoding the European guidelines –
What is the optimal treatment in first relapse?

Thomas CHALOPIN (Hematology, Tours)

Treatment options at first relapse of multiple myeloma:

From theory to practice through 3 clinical scenarios

Benjamin HÉBRAUD (Hematology, Toulouse)

Ocular toxicities of antibody-drug conjugates in hemato-oncology:
separating facts and myths

Marie-Caroline TRONE (Ophthalmology, Saint-Etienne)

Summary, perspectives (development plan) and Q&A

Alexis TALBOT (Immunology Hematology, Paris)



02:30- 04:00 p.m.....	Session 6: MULTIPLE MYELOMA Chair: Xavier LELEU (Hematology, Poitiers)	
	MRD immune Ludovic MARTINET (Oncogenomics and immunology, Toulouse)	15 min.
	Monoclonal gammopathy, a continuum from MGUS to MM, when to treat and for what goals and efforts Salomon MANIER (Hematology, Lille)	15 min.
	First-line therapy: quadruplet for whom and when? Arthur BOBIN (Hematology, Poitiers)	15 min.
	First therapeutic line, which could be "transplant deferred" and for which autograft remains the gold standard Claudio CERCHIONE (Hematology, Meldola - Italy)	15 min.
	CAR-T or Bispecific in Multiple Myeloma, which will be the most "treatment paradigm shift"? Alexis TALBOT (Immunology Hematology, Paris)	15 min.
	Discussion	15 min.

04:00 - 04:15 p.m.....COFFEE BREAK & MEET OUR PARTNERS 

04:15 - 04:25 p.m.....SHORT TALK : NEUTROPENIA ASSOCIATED WITH NEW ANTICANCER AGENTS
Chair: Gabriel ANThERIEU (Hematology, Oullins-Pierre-Bénite)



04:25 - 06:05 p.m.....	Session 7: CAR-T CELLS Chair: Marion ALCANTARA (Hematology, Saint-Cloud)	
	Predictive factors of toxicity after CAR-T cell therapy Rémy DULÉRY (Hematology, Paris)	20 min.
	Lessons learned after 6 years of RWE from the DESCAR-T Registry Gabriel BRISOU (Oncology Hematology, Marseille)	20 min.
	In vivo generation of CARs: how does it work? Els VERHOEYEN (Infectiology, Nice)	20 min.
	Cellular therapies (CARs, TCRs, TILs) for solid tumors: a reality? Amaury LERUSTE (Pediatrics, Paris)	20 min.
	Discussion	20 min.

FRIDAY 26th SEPTEMBER 2025

08:30 - 09:00 a.mOpening

09:00 - 10:20 a.m.....	Session 8: MYELOPROLIFERATIVE NEOPLASMS Chair: Mauricette MICHALLET (Hematology, Lyon)	
	Latest developments in the diagnosis and treatment of eosinophilia Andreas REITER (Oncology Hematology, Mannheim - Germany)	20 min.
	MPN: are young patients different ? Yan BEAUVERD (Hematology, Geneva - Switzerland)	20 min.
	Molecular complexity of MPNs: diagnostic and prognostic role Nabih MASLAH (Biological hematology, Paris)	20 min.
	Discussion	20 min.

10:20 - 10:50 a.m.....ORAL ABSTRACT

10:50 - 11:50 a.m.....ON THE ROAD TO PHILADELPHIA: NEW PERSPECTIVES IN CML AND MF

Chair: Mathieu WÉMEAU (Hematology, Lille)

Introduction

Mathieu WÉMEAU (Hematology, Lille)

Management of myelofibrosis in 2025: news and perspectives

Mathieu WÉMEAU (Hematology, Lille)

CML in 1st line: what innovations & prospects?

Valérie COITEUX (Hematology, Lille)

Conclusion

Mathieu WÉMEAU (Hematology, Lille)



11:50 am - 12:00 p.m.....BREAK - DISTRIBUTION OF LUNCH BOXES

12:00 - 01:00 p.m.....MYELOFIBROSIS AND CYTOPENIAS IN A PATIENT PREVIOUSLY TREATED WITH A JAK INHIBITOR: DOES EARLY INTERVENTION INFLUENCE THE OUTCOMES?

Chair: Mauricette MICHALLET (Hematology, Lyon)

Introduction

Mauricette MICHALLET (Hematology, Lyon)

Clinical burden of cytopenias in Myelofibrosis: what new data do we have?

Michael LOSCHI (Hematology, Nice)

Practical management of cytopenic profiles: insights and case-based discussions

Geoffroy VENTON (Hematology, Marseille)

Q&A et discussion



01:00 - 01:15 p.m.....COFFEE BREAK & MEET OUR PARTNERS 

01:15 - 02:35 p.m.....Session 9: CHRONIC LYMPHOCYTIC LEUKEMIA

Chair: Anne-Sophie MICHALLET (Hematology, Lyon)

Shared medical decision

Thérèse AURRAN-SCHLEINITZ (Hematology, Marseille) & Julia TINLAND (Philosophy, Marseille)

20 min.

RESIST data and a new approach to the management of doubly-exposed and doubly-refractory patients

Loïc YSEBAERT (Hematology, Toulouse)

20 min.

Recommendations for managing WM

Damien ROOS-WEIL (Hematology, Paris)

20 min.

Discussion

20 min.

02:35 - 02:45 p.mAWARD CEREMONY - CALL FOR ABSTRACT

02:45 - 03:00 p.m.....COFFEE BREAK & MEET OUR PARTNERS 

03:00 - 04:20 p.m.....Session 10: CHRONIC MYELOID LEUKEMIA

Chair: François-Xavier MAHON (Hematology, Bordeaux)

For whom, when and how to use allosteric inhibitors in CML?

Delphine RÉA (Hematology, Paris)

20 min.

Genomic analysis in CML: are we ready for clinical practice?

Ivan SLOMA (Oncology Hematology, Créteil)

20 min.

Is the ultimate goal in CML really TFR? Where are we?

François-Xavier MAHON (Hematology, Bordeaux)

20 min.

Discussion

20 min.

04:20 - 04:30 p.m.....CLOSING REMARKS